Hims & Hers Health (HIMS) has emerged as a disruptive force in telehealth, leveraging technology and personalization to address highly-personal health conditions while achieving scalable profitability ...

Hims & Hers Health stock is trading -39.24% below its average target price of $44.82 after marking a 1.0% during today's ...

Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $27.23, demonstrating a +1.04% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.13% gain on the ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like Ozempic.

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

Citi analyst Daniel Grosslight maintained a Buy rating on Owens & Minor (OMI – Research Report) today and set a price target of $11.00. The ...

Citi analyst Daniel Grosslight maintained a Hold rating on Cardinal Health (CAH – Research Report) today and set a price target of $140.00. The ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an ...

BofA Securities reiterated its Underperform rating on Hims & Hers Health (NYSE:HIMS), keeping its price target steady at $22, ...

In addition to Citi, McKesson also received a Buy from Bank of America Securities’s Allen Lutz in a report issued yesterday. However, on April 4, CFRA downgraded McKesson (NYSE: MCK) to a Hold. MCK ...